Center For Inherited Disease Research (CIDR) Standardizes On Illumina Technology For Genome-Wide Association Genotyping
New Offering Leverages CIDR's BeadLab Infrastructure to Supplement Custom SNP Genotyping Services
San Diego - Illumina, Inc. announced today that the Center for Inherited Disease Research (CIDR) will offer investigators a new genome-wide association (GWA) service based on Illumina's Sentrix HumanHap300 BeadChip and Infinium assay. The decision follows rigorous performance testing of the BeadChips and Infinium assay reagents as part of a Type 2 diabetes pilot study.
According to David Valle, M.D., Director, CIDR and Professor, Institute of Genetic Medicine, Johns Hopkins University, "Our evaluation of Illumina's WGA solution yielded impressive results and very high data quality. We observed call rates exceeding 99.6%, accuracy measures approaching 100%, and 99.85% concordance with HapMap genotypes. We look forward to collaborating with investigators on large-scale disease association studies."
The Sentrix HumanHap300 BeadChip analyzes over 317,000 tagSNPs on a single microarray. The BeadChip is powered by Illumina's Infinium assay, which enables intelligent selection and analysis of virtually any SNP locus. The high information content of the HumanHap300 SNP loci enables Illumina to achieve comprehensive genomic coverage with far fewer markers than competing approaches.
CIDR's adoption of Illumina technology for genome-wide association studies complements the Center's SNP linkage and custom genotyping services that use the Illumina Array Matrix and GoldenGate(R) assay. All SNP genotyping is performed within the Illumina BeadLab system, which features production-scale sample processing and uses LIMS (laboratory information management system) to integrate workflows and ensure positive sample tracking.
Commenting on CIDR's adoption of Illumina solutions for whole-genome genotyping, Jay Flatley, Illumina CEO and President, stated, "We've been working closely with David Valle, Kim Doheny, Ph.D., Director of Genotyping at CIDR and their CIDR team for nearly three years, and we're thrilled to extend our relationship into the large-scale disease association area. We're also very pleased with the ease with which CIDR researchers were able to integrate Infinium genotyping into the existing BeadLab infrastructure."
SOURCE: Illumina, Inc.